Details of the Drug Combinations

General Information of This Drug (ID: DMG3Y89)

Drug Name
Trabectedin   DMG3Y89
Synonyms Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)
Indication
Disease Entry ICD 11 Status REF
Leiomyosarcoma 2B58 Approved [1]
Liposarcoma 2B59 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Ovarian cancer 2C73 Phase 3 [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Trabectedin + Panobinostat DCIKDJB Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
------------------------------------------------------------------------------------
7 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Dexamethasone + Trabectedin DC2YLYV Dexamethasone Ovarian Neoplasms [5]
Dexamethasone + Trabectedin DCALDB7 Dexamethasone Endometrial Neoplasms [6]
Olaparib + Trabectedin DC4A0IC Olaparib Soft Tissue Sarcoma [7]
Trabectedin + Irinotecan DCVAB9V Irinotecan Ewing Sarcoma [8]
Venetoclax + Trabectedin DCFWL4S Venetoclax Refractory Chronic Lymphocytic Leukemia [9]
Olaparib + Trabectedin DC25P2Q Olaparib Cancers With DNA Repair-Deficiency [10]
Pazopanib + Trabectedin DCQH35C Pazopanib Locally Advanced Uterine Corpus Leiomyosarcoma [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 Trabectedin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2774).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT00050414) A Study of Trabectedin in Patients With Advanced Ovarian Cancer
6 ClinicalTrials.gov (NCT00050440) Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
7 ClinicalTrials.gov (NCT02398058) Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
8 ClinicalTrials.gov (NCT04067115) SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
9 ClinicalTrials.gov (NCT03884972) Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
10 ClinicalTrials.gov (NCT03127215) Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
11 ClinicalTrials.gov (NCT05432791) Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working